Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 29.0

Eligibility Criteria:
Inclusion Criteria:~Phase I part:~- Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease as determined by RECIST version 1.1, who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists~Phase II part:~* Patients with advanced/metastatic solid tumors, with at least one measurable lesion as determined by RECIST version 1.1, who have had disease progression following their last prior therapy and fit into one of the following groups:~* Group 1: NSCLC~* Group 2: Melanoma~* Group 3: Renal cancer~* Group 4: Mesothelioma~* Group 5: TNBC~* Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1~* Patient must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy.~Exclusion Criteria:~* History of severe hypersensitivity reactions to study treatment ingredients or other mAbs~* Active, known or suspected autoimmune disease~* Active infection requiring systemic antibiotic therapy~* HIV infection. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection~* Patients receiving chronic treatment with systemic steroid therapy, other than replacement-dose corticosteroids in the setting of adrenal insufficiency~* Patients receiving systemic treatment with any immunosuppressive medication~* Use of live vaccines against infectious disease within 4 weeks of initiation of study treatment~* Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment.~* Presence of symptomatic central nervous system (CNS) metastases or CNS metastases that require local CNS-directed therapy or increasing doses of corticosteroids within the prior 2 weeks~* History of drug-induced pneumonitis or current pneumonitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1: LAG525 1 mg/kg Q2W (Type: EXPERIMENTAL): Single-agent LAG525 1 mg/kg Q2W
- Phase 1: LAG525 3 mg/kg Q2W (Type: EXPERIMENTAL): Single-agent LAG525 3 mg/kg Q2W
- Phase 1: LAG525 5 mg/kg Q2W (Type: EXPERIMENTAL): Single-agent LAG525 5 mg/kg Q2W
- Phase 1: LAG525 10 mg/kg Q2W (Type: EXPERIMENTAL): Single-agent LAG525 10 mg/kg Q2W
- Phase 1: LAG525 15 mg/kg Q2W (Type: EXPERIMENTAL): Single-agent LAG525 15 mg/kg Q2W
- Phase 1: LAG525 240 mg Q2W (Type: EXPERIMENTAL): Single-agent LAG525 240 mg Q2W
- Phase 1: LAG525 400 mg Q2W (Type: EXPERIMENTAL): Single-agent LAG525 400 mg Q2W
- Phase 1: LAG525 3 mg/kg Q4W (Type: EXPERIMENTAL): Single-agent LAG525 3 mg/kg Q4W
- Phase 1: LAG525 5 mg/kg Q4W (Type: EXPERIMENTAL): Single-agent LAG525 5 mg/kg Q4W
- Phase 1: LAG525 10 mg/kg Q4W (Type: EXPERIMENTAL): Single-agent LAG525 10 mg/kg Q4W
- Phase 1: LAG525 400 mg Q4W (Type: EXPERIMENTAL): Single-agent LAG525 400 mg Q4W
- Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W (Type: EXPERIMENTAL): Combination LAG525 0.3 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)
- Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W (Type: EXPERIMENTAL): Combination LAG525 1 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)
- Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W (Type: EXPERIMENTAL): Combination LAG525 80 mg + PDR001 80 mg (Q2W/Q2W)
- Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W (Type: EXPERIMENTAL): Combination LAG525 80 mg + PDR001 240 mg (Q2W/Q2W)
- Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W (Type: EXPERIMENTAL): Combination LAG525 240 mg + PDR001 240 mg (Q2W/Q2W)
- Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W (Type: EXPERIMENTAL): Combination LAG525 240 mg + PDR001 300 mg (Q3W/Q3W)
- Phase 1: LAG525 400 mg Q3W + PDR001 300 mg Q3W (Type: EXPERIMENTAL): Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W)
- Phase 1: LAG525 600 mg Q3W + PDR001 300 mg Q3W (Type: EXPERIMENTAL): Combination LAG525 600 mg + PDR001 300 mg (Q3W/Q3W)
- Phase 1: LAG525 80 mg Q4W + PDR001 240 mg Q4W (Type: EXPERIMENTAL): Combination LAG525 80 mg + PDR001 240 mg (Q4W/Q4W)
- Phase 1: LAG525 400 mg Q4W + PDR001 400 mg Q4W (Type: EXPERIMENTAL): Combination LAG525 400 mg + PDR001 400 mg (Q4W/Q4W)
- Phase 1: LAG525 800 mg Q4W + PDR001 400 mg Q4W (Type: EXPERIMENTAL): Combination LAG525 800 mg + PDR001 400 mg (Q4W/Q4W)
- Phase 1: LAG525 1000 mg Q4W + PDR001 400 mg Q4W (Type: EXPERIMENTAL): Combination LAG525 1000 mg + PDR001 400 mg (Q4W/Q4W)
- Phase 1: LAG525 80 mg Q2W + PDR001 400 mg Q4W (Type: EXPERIMENTAL): Combination LAG525 80 mg + PDR001 400 mg (Q2W/Q4W)
- Phase 1: LAG525 240 mg Q2W + PDR001 400 mg Q4W (Type: EXPERIMENTAL): Combination LAG525 240 mg + PDR001 400 mg (Q2W/Q4W)
- Phase 1: LAG525 300 mg Q2W + PDR001 400 mg Q4W (Type: EXPERIMENTAL): Combination LAG525 300 mg + PDR001 400 mg (Q2W/Q4W)
- Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W (Type: EXPERIMENTAL): Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1
- Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W (Type: EXPERIMENTAL): Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1
- Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W (Type: EXPERIMENTAL): Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete